A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

Samankaltaisia teoksia

• Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials
  Tekijä: Ferguson, Gary T., et al.
  Julkaistu: (2019)
• Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
  Tekijä: James F. Donohue, et al.
  Julkaistu: (2020-05-01)
• Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
  Tekijä: Donohue, James F., et al.
  Julkaistu: (2020)
• Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
  Tekijä: Donohue, James, et al.
  Julkaistu: (2019)
• Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
  Tekijä: Donohue, James F., et al.
  Julkaistu: (2019)